
|Articles|June 20, 2019
June 2019 Digital Edition
Advertisement
Pipeline watch: we look closely at drugs in phase 2, phase 3 or recently approved for basal cell carcinoma and melanoma. Plus, treating patients with autism, and the physician's impact on regulations and pay.
Subscribe to Dermatology Times!
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Hilary Baldwin, MD, Highlights Emerging Acne and Rosacea Therapies at Elevate-Derm
2
Douglas DiRuggiero, PA-C, DMSc, Recognized at the Elevate-Derm Fall Conference
3
Education and Engagement Drive Momentum in Hair Disorders
4
Advancing Topical Stewardship and Expanding Nonsteroidal Options
5



















